topics 314-a 
SpicyIP
OCTOBER 26, 2022
After a few sessions on conceptual and theoretical ideas around IP, this set of sessions will now take the class on a different not-so-theoretical topic and deliberates upon IP issues that crop up around clinical trial test data, drug innovation, Indian drug regulatory regulation etc. WHO is the authority? Why is it even in the market? .
Patently-O
FEBRUARY 24, 2022
Rather, any new grant this term will very likely be pushed back to the October 2022 Term for hearing and decision. Still, there are a number of important patent cases pending before the court. Lets talk them through. The request, known as a CVSG, typically requires four of the nine Justices — the same number needed to grant certiorari.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LexBlog IP
FEBRUARY 18, 2024
all of the controversial topics have been dropped). ANPRM an Unnecessary Slog to a Small Rule Package It has been almost a year since the Patent Trial & Appeal Board (PTAB) released its Advanced Notice of Proposed Rulemaking (ANPRM) on AIA trial practices. Maybe …the clock on the Vidal administration is ticking. What happened?
The IPKat
DECEMBER 29, 2023
Findings on specific issues and topics Data regarding the stack Data regarding the stack could not be obtained directly from ETSI. This is Trial E, one of the six related trials between Optis and Apple. Trial E determined in particular the terms of a FRAND licence and the conduct of the parties in the negotiations.
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 7, 2022
10 YEARS AFTER THE AMERICA INVENTS ACT (AIA), THE PATENT TRIAL AND APPEAL BOARD (PTAB) ENDURES. After a heady 2020, 2021 proved to be a return to normalcy for the PTAB. While there was significant excitement early in the year about how the Supreme Court would rule in Arthrex , its decision in June mostly maintained the status quo. Download a PDF.
Expert insights. Personalized for you.
118 
Let's personalize your content